Bioasis Technologies Inc.

Equities

BTI

CA09064N1033

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 12:00:00 2024-03-21 pm EDT			5-day change	1st Jan Change
0.005 ^CAD	-.--%		-.--%	-.--%

2023	Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A	CI
2023	Bioasis Technologies Slumps 25% As Provides Update on Financial Position	MT

Bioasis Technologies Inc. Reports Earnings Results for the Full Year Ended February 28, 2022

June 14, 2022 at 07:04 pm EDT

Bioasis Technologies Inc. reported earnings results for the full year ended February 28, 2022. For the full year, the company reported revenue was CAD 0.037725 million compared to CAD 4.08 million a year ago. Net loss was CAD 2.96 million compared to net income of CAD 0.69841 million a year ago.

Basic loss per share from continuing operations was CAD 0.04 compared to basic earnings per share from continuing operations of CAD 0.01 a year ago.

Latest news about Bioasis Technologies Inc.

Bioasis Technologies Inc. Announces Terminating the Non-Exclusive Research Collaboration and Licensing Agreement with Chiesi Farmaceutici S.P.A	23-06-20	CI
Bioasis Technologies Slumps 25% As Provides Update on Financial Position	23-02-06	MT
Bioasis Technologies Provides Update on Financial Position; Down 11% on Friday	23-02-06	MT
Bioasis Technologies Explores and Evaluates Strategic Alternatives	23-01-24	CI
Midatech Pharma plc cancelled the acquisition of Bioasis Technologies Inc..	23-01-22	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2022	23-01-19	CI
Midatech Pharma plc entered into a definitive agreement to acquire Bioasis Technologies Inc. from The Lind Partners, LLC and others for $5.5 million.	22-12-12	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2022	22-10-28	CI
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2022	22-07-29	CI
Bioasis Technologies Buys Phase 2 Ready Rare Orphan EGF Assets From Norwegian Company	22-06-16	MT
Bioasis Technologies Inc. Reports Earnings Results for the Full Year Ended February 28, 2022	22-06-14	CI
Bioasis Technologies Inc. Auditor Raises 'Going Concern' Doubt	22-06-13	CI
Bioasis Technologies and Neuramedy of South Korea Enter into Research Collaboration and License Agreement	22-05-11	MT
Bioasis Technologies Inc. and Neuramedy Co Ltd Enter into Research Collaboration and License Agreement	22-05-10	CI
Bioasis Technologies to Collaborate on Research with Johnson & Johnson's Janssen Biotech Subsidiary	22-04-11	MT
Bioasis Technologies Inc. Enters Research Collaboration with Janssen Biotech, Inc	22-04-11	CI
Bioasis Technologies Raises C$0.2 Million in a Private Placement of Shares	22-02-17	MT
Bioasis Technologies Inc. announced that it has received CAD 0.2002 million in funding	22-02-16	CI
Bioasis Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2021	22-01-20	CI
Bioasis Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2021	21-10-28	CI
Bioasis Technologies Inc.(TSXV:BTI) dropped from S&P/TSX Venture Composite Index	21-10-18	CI
Bioasis Technologies Brief: nnounces Allowance of Japanese Patent Application in Japan Relating to Fusion Protein Comprising Iduronate-2-sulfatase	21-08-09	MT
Bioasis Technologies Inc. Reports Earnings Results for the First Quarter Ended May 31, 2021	21-07-29	CI
Bioasis Technologies Inc. Appoints Jeffrey Sprouse as Preclinical Program Manager	21-07-20	CI
Bioasis Technologies : Says Study Shows Efficacy of its Peptide for Delivering Drugs to the Central Nervous System	21-07-07	MT

Chart Bioasis Technologies Inc.

Duration

Period

More charts

Company Profile

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
BIOASIS TECHNOLOGIES INC.	-.--%	290K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research